[Gene expression of TGF-beta1 and its type II receptor in hepatocellular carcinoma]

Area of Science:

• Oncology
• Molecular Biology
• Hepatology

Background:

• Transforming growth factor-beta1 (TGF-beta(1)) is a key regulator of cell growth and differentiation.
• Dysregulation of TGF-beta signaling is implicated in various cancers, including hepatocellular carcinoma (HCC).
• Understanding the expression patterns of TGF-beta(1) and its receptor in HCC is crucial for identifying potential therapeutic targets.

Purpose of the Study:

• To investigate the gene expression of TGF-beta(1) and its type II receptor (TGF-beta R II) in hepatocellular carcinoma (HCC).
• To correlate the expression levels with clinicopathological features of HCC.

Main Methods:

• Gene expression analysis of TGF-beta(1) and TGF-beta R II at both mRNA and protein levels.
• Utilized reverse transcription-PCR for mRNA detection and immunohistochemistry for protein detection.
• Studied 30 cases of HCC tissue and surrounding liver tissue.

Main Results:

• TGF-beta(1) mRNA expression showed no significant difference between HCC and surrounding tissues.
• TGF-beta(1) protein expression was significantly decreased in HCC tissues compared to surrounding tissues (P < 0.01).
• TGF-beta R II mRNA expression was significantly reduced in HCC tissues (P < 0.01).
• Lower TGF-beta R II mRNA expression correlated with poorer tumor differentiation (P < 0.01) and increased risk of portal vein metastasis and cancer embolus (P < 0.05).

Conclusions:

• Hepatocellular carcinoma exhibits defects in TGF-beta(1) signaling, specifically at the protein level for TGF-beta(1) and mRNA level for TGF-beta R II.
• These molecular alterations may contribute to the loss of negative growth regulation in tumoral hepatocytes.
• The findings highlight the potential role of TGF-beta(1) pathway dysregulation in HCC progression and metastasis.